CapsoVision, Inc. Announces Amendment to Sample Purchase Agreement with Canon Inc. for CMOS Image Sensor Development 5

CapsoVision, Inc. Announces Amendment to Sample Purchase Agreement with Canon Inc.

Key Points:

CapsoVision, Inc. (Nasdaq: CV) has entered into an amendment to its Sample Purchase Agreement with Canon Inc., a leading Japanese corporation.
The amendment pertains to the development and procurement of complementary metal-oxide-semiconductor (CMOS) image sensor samples for CapsoVision’s evaluation, including clinical trials and product development.
This agreement could impact CapsoVision’s product pipeline and future revenues, making it a potentially price-sensitive development for shareholders.

Details of the Material Definitive Agreement

CapsoVision, Inc. (the “Company”), a developer of advanced medical imaging solutions, filed a Form 8-K with the Securities and Exchange Commission on March 13, 2026, to announce a new amendment to its existing Sample Purchase Agreement with Canon Inc. The amendment, effective March 9, 2026, is directly related to the ongoing collaboration between the two companies for the development of advanced CMOS image sensors. These sensors are essential components in CapsoVision’s medical imaging products.

The original agreement, as previously reported on July 15, 2025, established the framework for Canon to develop and supply sensor samples tailored to CapsoVision’s requirements. The amendment clarifies the payment terms and confirms the remaining development fees owed by CapsoVision to Canon. The amendment also specifies that, despite an increase in the total fee, the “Additional Amount” (as defined in Section 12.5 of the Agreement) remains unchanged and all other terms under the original Agreement remain in full force and effect.

Strategic and Shareholder Impact

Why this matters for investors:

This collaboration with Canon, a global leader in imaging and optics, could significantly enhance CapsoVision’s product offerings and competitive position in the medical device market.
Successful development and integration of the new CMOS sensors may accelerate CapsoVision’s ability to bring new and innovative medical imaging products to market, potentially driving revenue growth and expanding market share.
The amendment provides greater clarity on financial commitments and project scope, reducing uncertainty around the partnership’s execution.
There is no indication of changes to the company’s emerging growth company status or any new risk factors in this filing.

Other Disclosures

CapsoVision’s common stock, with a \$0.001 par value per share, continues to be listed and traded under the symbol “CV” on The Nasdaq Stock Market LLC.
As of the filing, CapsoVision affirms its status as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
No other material changes or risk factors are disclosed within this filing.

Exhibits Filed

10.1: Amendment to Sample Purchase Agreement, dated March 9, 2026, between CapsoVision, Inc. and Canon Inc.
104: Cover Page Interactive Data File (embedded within the Inline XBRL document)

Management Sign-Off

The filing is signed by Kang-Huai (Johnny) Wang, President and Chief Executive Officer of CapsoVision, Inc., reflecting management’s direct involvement and endorsement of the amended agreement.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making investment decisions. The information is based on the company’s regulatory filings and is subject to change without notice.

CapsoVision, Inc. Announces Amendment to Sample Purchase Agreement with Canon Inc. for CMOS Image Sensor Development 5